Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 115529935 | 11552993 | 5 | F | 20150830 | 20160913 | 20150925 | 20160922 | EXP | CA-AMGEN-CANSP2015077636 | AMGEN | 65.00 | YR | E | F | Y | 0.00000 | 20160922 | OT | CA | CA |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 115529935 | 11552993 | 1 | PS | NEUPOGEN | FILGRASTIM | 1 | Unknown | 7 DAYS POST CHEMO | 103353 | SOLUTION FOR INJECTION | |||||||||
| 115529935 | 11552993 | 2 | SS | PERJETA | PERTUZUMAB | 1 | Intravenous (not otherwise specified) | 840 MG, 1 IN 3 WK | 0 | 840 | MG | SOLUTION FOR INFUSION | Q3W | ||||||
| 115529935 | 11552993 | 3 | SS | PERJETA | PERTUZUMAB | 1 | Intravenous (not otherwise specified) | 420 MG, 1 IN 3 WK | 0 | 420 | MG | SOLUTION FOR INFUSION | Q3W | ||||||
| 115529935 | 11552993 | 4 | SS | HYDROCHLOROTHIAZIDE W/TELMISARTAN | HYDROCHLOROTHIAZIDETELMISARTAN | 1 | Oral | UNK | 0 | TABLET | |||||||||
| 115529935 | 11552993 | 5 | SS | DOCETAXEL. | DOCETAXEL | 1 | Intravenous (not otherwise specified) | UNK | 0 | ||||||||||
| 115529935 | 11552993 | 6 | C | HYDROCHLOROTHIAZIDE. | HYDROCHLOROTHIAZIDE | 1 | UNK | 0 | |||||||||||
| 115529935 | 11552993 | 7 | C | 5-FU | FLUOROURACIL | 1 | UNK | 0 | |||||||||||
| 115529935 | 11552993 | 8 | C | EPIRUBICIN | EPIRUBICIN | 1 | Intravenous (not otherwise specified) | UNK | 0 | ||||||||||
| 115529935 | 11552993 | 9 | C | CYCLOPHOSPHAMIDE. | CYCLOPHOSPHAMIDE | 1 | UNK | 0 | |||||||||||
| 115529935 | 11552993 | 10 | C | TELMISARTAN. | TELMISARTAN | 1 | UNK | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 115529935 | 11552993 | 1 | Product used for unknown indication |
| 115529935 | 11552993 | 2 | Breast cancer |
| 115529935 | 11552993 | 4 | Hypertension |
| 115529935 | 11552993 | 5 | Product used for unknown indication |
| 115529935 | 11552993 | 10 | Blood pressure measurement |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 115529935 | 11552993 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 115529935 | 11552993 | Blood potassium decreased | |
| 115529935 | 11552993 | Diarrhoea | |
| 115529935 | 11552993 | Dizziness | |
| 115529935 | 11552993 | Hypotension | |
| 115529935 | 11552993 | Influenza like illness | |
| 115529935 | 11552993 | Unresponsive to stimuli | |
| 115529935 | 11552993 | Vomiting | |
| 115529935 | 11552993 | White blood cell count abnormal |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 115529935 | 11552993 | 2 | 20150714 | 0 | ||
| 115529935 | 11552993 | 3 | 20150804 | 0 |